-
Sector Analysis
Chronic Kidney Disease: Epidemiology Report and Forecast to 2035
Chronic kidney disease (CKD), or chronic renal disease (International Classification of Diseases 10th Revision [ICD-10] code = N18), is a condition characterized by a gradual loss of kidney function over time. This leads to the accumulation of excess fluid and waste in the body. In the early stages, CKD is a largely asymptomatic condition. As the disease progresses, symptoms worsen and eventually lead to kidney failure (Centers for Disease Control and Prevention, 2024). Advanced CKD can lead to dangerous levels...
-
Sector Analysis
Male Infertility Major Markets: Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035
GlobalData forecasts that the diagnosed prevalent cases of male infertility are expected to slightly decline from 3,957,575 cases in 2025 to 3,932,895 cases in 2035, at a negative annual growth rate (AGR) of 0.06% across the seven major pharmaceutical markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). Male infertility is a medical condition, including disorders such as oligo-,astheno-, terato-, and azoospermia. The condition has low prevalence and can be caused by numerous factors, including genetics, environmental, or as...
-
Sector Analysis
Primary Biliary Cholangitis (Primary Biliary Cirrhosis): Market View, Current and Future Competitive Landscape
This report provides a data-driven overview of the current and future competitive landscape in Primary Biliary Cholangitis (Primary Biliary Cirrhosis) Therapeutics. In 2025, there were more than 1.12 million diagnosed prevalent cases of PBC in the 16 countries covered in GlobalData’s epidemiology forecast. Currently, the PBC market is saturated with generic drugs and has a limited number of approved drugs available to treat PBC. The DR pipeline holds 32 molecules, with no assets in the pre-registration stage, four assets in...
-
Thematic Analysis
Evolution of GLP-1RAs - From Breakthrough to Growth: Strategic Intelligence
GLP 1RA therapies have shifted from treating T2D to becoming a multi indication therapy. GLP 1RAs were originally developed for type 2 diabetes (Byetta in 2005), and since 2014 they have expanded beyond T2D, starting with obesity (Saxenda) and then additional indications. GLP 1RA sales increased significantly from 2022 onwards, driven by newer therapies targeting obesity. This growth was driven by the entry and rapid uptake of Mounjaro and Wegovy (Mounjaro: ~$0.5B in 2022 to ~$23B in 2025; Wegovy: ~$0.9B...
-
Q1 2026 CRO Activity and Intel Report
This report offers an in-depth analysis of the contract research organization (CRO) industry, categorized by geography, therapeutic area, and phase of development for Q1 2026.
-
Sector Analysis
Bio/Pharmaceutical Outsourcing Report, April 2026
The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
-
Sector Analysis
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2026: Conference Highlights
Why Does ESCMID Global 2026 Matter for Your Business? ESCMID Global remains one of the most influential infectious diseases conferences for tracking emerging therapies, clinical data, and competitive developments across viral and fungal disease markets. This report provides a focused analysis of the key presentations, scientific sessions, and industry-sponsored symposia featured at ESCMID Global 2026, held in Munich, Germany between April 17 and 21. You can use this report to: Understand emerging trends in infectious disease therapeutics Analyze late-stage clinical...
-
Product Insights
Alzheimer's Disease: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Alzheimer's Disease - Global Clinical Trials Review, 2026" provides an overview of Alzheimer's Disease Clinical trials scenario. This report provides top line data relating to the clinical trials on Alzheimer's Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Amyotrophic Lateral Sclerosis: Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Amyotrophic Lateral Sclerosis - Global Clinical Trials Review, 2026" provides an overview of Amyotrophic Lateral Sclerosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Amyotrophic Lateral Sclerosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Glioblastoma Multiforme (GBM): Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Glioblastoma Multiforme (GBM) - Global Clinical Trials Review, 2026" provides an overview of Glioblastoma Multiforme (GBM) Clinical trials scenario. This report provides top line data relating to the clinical trials on Glioblastoma Multiforme (GBM). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.